肝腎症候群におけるhigh flow dialysate continuous hemodiafiltration(<特集>急性臓器障害に対するアフェレシス)

概要

論文の詳細を見る
Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis as well as acute liver failure or alcoholic hepatitis, and is mainly triggered by bacterial infection, bleeding and deterioration of liver function. HRS had traditionally been viewed as a manifestation of the terminal stage of hepatic failure and an irreversible syndrome. However recent studies on HRS have clarified the pathophysiology of this syndrome. The elucidation of mechanism has led to development of new beneficial therapeutic strategies, such as liver transplantation, vasoconstrictor therapy, transjugular intrahepatic portosystemic shunt (TIPS), and blood purification therapy. Furthermore, our preliminary data on high flow dialysate continuous hemodiafiltration (HFCHDF) showed the improvement of hepatic encephalopathy and renal function in HRS patients. These results suggest that HFCHDF should be a new therapeutic strategy for HRS, and further study on HFCHDF in HRS patients is needed.
日本アフェレシス学会の論文
2007-10-31